- The P-IIIb VARSITY study involves assessing of Entyvio (vedolizumab, IV) vs Humira (adalimumab, SC) in 769 patients (anti-TNFα-naïve patients & anti-TNFα-experienced patients) with moderately to severely active UC for 52wks.
- The P-IIIb VARSITY results: @52wks. Clinical remission rates (31.3% vs 22.5%), CRR in anti-TNFα-naïve & experienced patients (34.2% & 20.3% vs 24.3% & 16%); CRR @14wks. (26.6% vs 21.2%); Durable clinical remission (18.3% vs 11.9%); % of mucosal healing (39.7% vs 27.7%); improvement in QoL (52.0% vs 42.2%); ≥16-point improvement in IBDQ; published in NEJM
- Entyvio (IV) is a gut-selective mAb, designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not (VCAM-1) and has received marketing authorization in 60+ countries including the US and EU
Click here to read full press release/ article | Ref: Takeda | Image: Robus